In early April, Novartis drug Vanrafia won accelerated FDA approval as ... becoming the first FDA-approved treatment for C3 glomerulopathy, an ultra-rare kidney disease that can progress to ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia (atrasentan) is the first drug in the selective ...

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

If Regulus’ lead drug candidate, farabursen, gets regulatory approval ... Novartis – which has its U.S. headquarters in East Hanover – said the move will strengthen its lineup of kidney ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...

CVS's decision impacts Eli Lilly shares as it drops Zepbound, while Biogen reports strong sales in rare disease drugs. CVS revises profit outlook upwards, and the FDA approves drugs from J&J and UK’s ...

Shares of Regulus more than doubled to $7.8. The deal, expected to bolster Novartis' lineup of kidney disease drugs ... the only treatment approved by the U.S. Food and Drug Administration in ...